미국의 임상시험 시장 규모, 점유율, 동향 분석 보고서 : 단계별, 적응증별, 시험 설계별, 스폰서별, 서비스별, 부문별 예측(2025-2030년)

U.S. Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Indication, By Study Design, By Indication by Study Design, By Sponsor, By Service, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,287,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,679,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,465,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

미국의 임상시험 시장 성장 및 동향:

Grand View Research, Inc.의 최신 보고서에 따르면 미국의 임상시험 시장 규모는 2030년까지 577억 9,000만 달러에 달할 것으로 추정되며, 2025년부터 2030년까지 6.30%의 CAGR을 기록할 것으로 예상됩니다.

미국 내 만성질환 유병률 증가와 임상시험에 대한 수요 증가가 시장 성장을 견인하고 있습니다.

암 진단을 받는 사람의 수는 향후 8년 동안 몇 배로 증가할 것으로 예상됩니다. 종양학 분야의 연구로 생존자는 상당히 증가했지만, 암 환자 수는 전 세계적으로 증가할 것으로 예상됩니다. 췌장암은 예후가 좋지 않아 생존기간이 1-3년에 불과합니다. 매일 약 13명이 소화관 간질 종양 진단을 받습니다. 미국에서는 매년 60,000건 이상의 신세포암이 새로 진단되고 있으며, 이는 암의 유병률 증가와 다양한 암에 대한 효과적인 치료법의 필요성을 보여줍니다. 미국 내 질환의 유행으로 인해 연구개발에 대한 투자가 증가하여 산업 성장을 촉진할 것으로 예상됩니다.

COVID-19로 인해 새로운 연구 프로젝트가 중단되고 다른 질병에 자원이 재분배되고 있습니다. 국경이 봉쇄되면서 임상시험 샘플의 공급망도 중단되었습니다. 따라서 이 시장은 혼란스럽다. 그러나 COVID-19의 대응은 임상시험의 수행을 변화시키는 새로운 시장 개척을 가져왔습니다. 분산형/가상 임상시험은 그러한 방법 중 하나입니다. 가상 임상시험은 현재 COVID-19 시나리오에서 매우 중요한 역할을 하고 있습니다. 가상 방문과 원격 환자 모니터링을 통해 참가자들은 위험을 최소화할 수 있는 선택권과 안도감을 얻을 수 있습니다. 모니터링 가젯, 소프트웨어 도구 및 휴대전화를 통해 참가자는 집에서 실험을 완료할 수 있습니다.

미국의 임상시험 시장 보고서 하이라이트

• 2024년, 임상 3상 시험이 가장 높은 매출 점유율을 차지했습니다. 이러한 임상시험은 300-3000명의 참가자를 대상으로 하고 기간이 길기 때문에 더 중요합니다. 따라서 가장 비용이 많이 드는 단계입니다.
• 시험 설계별로는 중재 설계 부문이 2024년 미국 시장에서 가장 큰 매출 점유율을 차지하며 미국 시장을 장악했습니다.
• 적응증별로는 종양학 부문이 2024년 가장 큰 매출 비중을 차지했습니다. 이러한 성장은 암 환자의 증가에 기인합니다. 이에 따라 종양학 임상시험에 많은 비용이 지출되고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 미국의 임상시험 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 보조 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 규제 상황
• 기술적 상황
• 가격 모델 분석
• 임상시험 수량 분석, 2024년
• 미국의 임상시험 시장 분석 툴
  • Porter's Five Forces 분석
  • PESTEL 분석
  • COVID-19의 영향 분석
• 단계별 제품 파이프라인 분석
  • 개발중인 치료제
  • 개발중인 백신

제4장 미국의 임상시험 시장 : 단계 추정·동향 분석

• 부문 대시보드
• 임상시험 시장 : 단계 변동 분석과 시장 점유율, 2024년과 2030년
• 단계 I
• 단계 II
• 단계 III
• 단계 IV

제5장 미국의 임상시험 시장 : 시험 디자인 추정·동향 분석

• 부문 대시보드
• 임상시험 시장 : 연구 디자인 변동 분석과 시장 점유율, 2024년과 2030년
• 개입적
• 관찰적
• 확장 액세스

제6장 미국의 임상시험 시장 : 적응증 추정·동향 분석

• 부문 대시보드
• 임상시험 시장 : 적응증 변동 분석과 시장 점유율, 2024년과 2030년
• 자가면역/염증
  • 류마티스 관절염
  • 다발성 경화증
  • 골관절염
  • 과민성대장증후군(IBS)
  • 기타
• 통증 관리
  • 만성 통증
  • 급성 통증
• 종양학
  • 혈액암
  • 고형 종양
  • 기타
• 중추신경계 증상
  • 간질
  • 파킨슨병(PD)
  • 헌팅턴병
  • 뇌졸중
  • 외상성 뇌손상(TBI)
  • 근위축성측색경화증(ALS)
  • 근육 재생
  • 기타
• 당뇨병
• 비만
• 심혈관
• 기타

제7장 미국의 임상시험 시장 : 시험 디자인별, 적응증별 추정·동향 분석

• 부문 대시보드
• 임상시험 시장 : 적응증 변동 분석과 시장 점유율, 2024년과 2030년
• 자가면역/염증
  • 개입적
  • 관찰적
  • 확장 액세스
• 통증 관리
  • 개입적
  • 관찰적
  • 확장 액세스
• 종양학
  • 개입적
  • 관찰적
  • 확장 액세스
• 중추신경계 증상
  • 개입적
  • 관찰적
  • 확장 액세스
• 당뇨병
  • 개입적
  • 관찰적
  • 확장 액세스
• 비만
  • 개입적
  • 관찰적
  • 확장 액세스
• 심혈관
  • 개입적
  • 관찰적
  • 확장 액세스
• 기타
  • 개입적
  • 관찰적
  • 확장 액세스

제8장 미국의 임상시험 시장 : 서비스 추정·동향 분석

• 부문 대시보드
• 임상시험 시장 : 스폰서 변동 분석과 시장 점유율, 2024년과 2030년
• 프로토콜 설계
• 사이트 식별
• 환자 모집
• 실험실 서비스
• 바이오 분석 시험 서비스
• 임상시험 데이터 관리 서비스
• 기타

제9장 미국의 임상시험 시장 : 스폰서 추정·동향 분석

• 부문 대시보드
• 임상시험 시장 : 스폰서 변동 분석과 시장 점유율, 2024년과 2030년
• 제약·바이오의약품 기업
• 의료기기 기업

제10장 경쟁 상황

• 시장 진출 기업 분류
  • 시장 리더
  • 신흥 기업
• 시장 상황 분석, 2024년
• 주요 기업 개요
  • IQVIA
  • Fortrea Inc.
  • PAREXEL International Corporation
  • Thermo Fisher Scientific Inc.
  • Charles River Laboratories
  • ICON Plc
  • Wuxi AppTec Inc.
  • Medpace
  • Syneos Health
  • AstraZeneca
  • Merck &Co.
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Pfizer
  • Caidya

ksm

영문 목차

영문목차

U.S. Clinical Trials Market Growth & Trends:

The U.S. clinical trials market size is estimated to reach USD 57.79 billion by 2030, registering a CAGR of 6.30% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of chronic disease and growing demand for clinical trials in the U.S. is boosting the growth of the market.

The number of people diagnosed with cancer is expected to increase multi-fold in the coming eight years. Although survivors have increased considerably owing to research in the oncology field, the number of cancer patients is expected to increase across the world. Pancreatic cancer has a poor prognosis with a survival of only 1 to 3 years. Approximately 13 people are diagnosed with GI stromal tumors each day. More than 60, 000 new cases of renal cell carcinoma are diagnosed every year in the U.S. Hence, representing an increasing prevalence of cancer and the need for effective treatments against various types of cancer. Investment in R&D is expected to grow owing to the disease prevalence across the U.S. thereby boosting the industry's growth.

The COVID-19 pandemic has halted new research projects and reallocated resources for other diseases. The supply chain for clinical trial samples has also been interrupted as a result of blocked borders. Hence, this market is disrupted. However, the COVID-19 response has resulted in new developments on the market that have transformed the conduct of clinical trials. Decentralized/virtual clinical trials are one such technique. Virtual trials have a very important role in the current COVID-19 scenario. As a result of the virtual visit and remote patient monitoring, participants have a choice and peace of mind to minimize risks. Monitoring gadgets, software tools, and mobile phones enable participants to complete the experiment from their homes.

U.S. Clinical Trials Market Report Highlights:

• In 2024, the phase III dominated the market with highest revenue share. These trials are more crucial as they involve 300 to 3000 participants and have a longer period of time. Thus, it is the most expensive phase
• By study design, the interventional design segment dominated the U.S. market and accounted for the largest revenue share in 2024.
• Based on indication, the oncology segment held the largest revenue share in 2024. This growth is due to the growing number of cases of cancer. Thus, a large amount of expenditure is spent on oncology clinical trials.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.6.2. Volume price analysis (Model 2)
    • 1.6.2.1. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives
  • 1.9.1. Objective 1
  • 1.9.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Clinical Trials Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Regulatory Landscape
• 3.4. Technological Landscape
• 3.5. Pricing Model Analysis
• 3.6. Clinical Trial Volume Analysis, 2024
• 3.7. U.S. Clinical Trials Market Analysis Tools
  • 3.7.1. Porter's Five Forces Analysis
  • 3.7.2. PESTEL Analysis
  • 3.7.3. COVID-19 Impact Analysis
• 3.8. Product Pipeline Analysis by Stage
  • 3.8.1. Therapeutics in Development
  • 3.8.2. Vaccines in Development

Chapter 4. U.S. Clinical Trials Market: Phase Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Clinical Trials Market: Phase Movement Analysis & Market Share, 2024 & 2030
• 4.3. Phase I
  • 4.3.1. Phase I Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Phase II
  • 4.4.1. Phase II Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Phase III
  • 4.5.1. Phase III Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Phase IV
  • 4.6.1. Phase IV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Clinical Trials Market: Study Design Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Clinical Trials Market: Study Design Movement Analysis & Market Share, 2024 & 2030
• 5.3. Interventional
  • 5.3.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Observational
  • 5.4.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Expanded Access
  • 5.5.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Clinical Trials Market: Indication Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Clinical Trials Market: Indication Movement Analysis & Market Share, 2024 & 2030
• 6.3. Autoimmune/Inflammation
  • 6.3.1. Autoimmune/Inflammation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.2. Rheumatoid Arthritis
    • 6.3.2.1. Rheumatoid Arthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.3. Multiple Sclerosis
    • 6.3.3.1. Multiple Sclerosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.4. Osteoarthritis
    • 6.3.4.1. Osteoarthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.5. Irritable Bowel Syndrome (IBS)
    • 6.3.5.1. Irritable Bowel Syndrome (IBS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.6. Others
    • 6.3.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Pain Management
  • 6.4.1. Pain Management Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.2. Chronic Pain
    • 6.4.2.1. Chronic Pain Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Acute Pain
    • 6.4.3.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Oncology
  • 6.5.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. Blood Cancer
    • 6.5.2.1. Blood Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Solid Tumors
    • 6.5.3.1. Solid Tumors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. Others
    • 6.5.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. CNS Conditions
  • 6.6.1. CNS Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Epilepsy
    • 6.6.2.1. Epilepsy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. Parkinson's Disease (PD)
    • 6.6.3.1. Parkinson's Disease (PD) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. Huntington's Disease
    • 6.6.4.1. Huntington's Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. Stroke
    • 6.6.5.1. Stroke Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. Traumatic Brain Injury (TBI)
    • 6.6.6.1. Traumatic Brain Injury (TBI) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Amyotrophic Lateral Sclerosis (ALS)
    • 6.6.7.1. Amyotrophic Lateral Sclerosis (ALS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.8. Muscle Regeneration
    • 6.6.8.1. Muscle Regeneration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.9. Others
    • 6.6.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Diabetes
  • 6.7.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. Obesity
  • 6.8.1. Obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.9. Cardiovascular
  • 6.9.1. Cardiovascular Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.10. Others
  • 6.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. U.S. Clinical Trials Market: Indication by Study Design Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Clinical Trials Market: Indication Movement Analysis & Market Share, 2024 & 2030
• 7.3. Autoimmune/Inflammation
  • 7.3.1. Autoimmune/Inflammation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2. Interventional
    • 7.3.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.3. Observational
    • 7.3.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.4. Expanded Access
    • 7.3.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Pain Management
  • 7.4.1. Pain Management Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. Interventional
    • 7.4.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Observational
    • 7.4.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Expanded Access
    • 7.4.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Oncology
  • 7.5.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. Interventional
    • 7.5.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Observational
    • 7.5.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. Expanded Access
    • 7.5.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. CNS Conditions
  • 7.6.1. CNS Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Interventional
    • 7.6.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. Observational
    • 7.6.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. Expanded Access
    • 7.6.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Diabetes
  • 7.7.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Interventional
    • 7.7.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Observational
    • 7.7.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.4. Expanded Access
    • 7.7.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Obesity
  • 7.8.1. Obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.2. Interventional
    • 7.8.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Observational
    • 7.8.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. Expanded Access
    • 7.8.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.9. Cardiovascular
  • 7.9.1. Cardiovascular Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.2. Interventional
    • 7.9.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.3. Observational
    • 7.9.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.4. Expanded Access
    • 7.9.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.10. Others
  • 7.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.10.2. Interventional
    • 7.10.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.10.3. Observational
    • 7.10.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.10.4. Expanded Access
    • 7.10.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. U.S. Clinical Trials Market: Service Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Clinical Trials Market: Sponsor Movement Analysis & Market Share, 2024 & 2030
• 8.3. Protocol Designing
  • 8.3.1. Protocol Designing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.4. Site Identification
  • 8.4.1. Site Identification Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Patient Recruitment
  • 8.5.1. Patient Recruitment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Laboratory Services
  • 8.6.1. Laboratory Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.7. Bioanalytical Testing Services
  • 8.7.1. Bioanalytical Testing Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.8. Clinical Trial Data Management Services
  • 8.8.1. Clinical Trial Data Management Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.9. Others
  • 8.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. U.S. Clinical Trials Market: Sponsor Estimates & Trend Analysis

• 9.1. Segment Dashboard
• 9.2. Clinical Trials Market: Sponsor Movement Analysis & Market Share, 2024 & 2030
• 9.3. Pharmaceutical & Biopharmaceutical Companies
  • 9.3.1. Pharmaceutical & Biopharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.4. Medical Device Companies
  • 9.4.1. Medical Device Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Market Participant Categorization
  • 10.1.1. Market Leaders
  • 10.1.2. Emerging Players
• 10.2. Market Position Analysis, 2024
• 10.3. Key Company Profiles
  • 10.3.1. IQVIA
    • 10.3.1.1. Company Overview
    • 10.3.1.2. Financial Performance
    • 10.3.1.3. Service Benchmarking
    • 10.3.1.4. Strategic Initiatives
  • 10.3.2. Fortrea Inc.
    • 10.3.2.1. Company Overview
    • 10.3.2.2. Financial Performance
    • 10.3.2.3. Service Benchmarking
    • 10.3.2.4. Strategic Initiatives
  • 10.3.3. PAREXEL International Corporation
    • 10.3.3.1. Company Overview
    • 10.3.3.2. Financial Performance
    • 10.3.3.3. Service Benchmarking
    • 10.3.3.4. Strategic Initiatives
  • 10.3.4. Thermo Fisher Scientific Inc.
    • 10.3.4.1. Company Overview
    • 10.3.4.2. Financial Performance
    • 10.3.4.3. Service Benchmarking
    • 10.3.4.4. Strategic Initiatives
  • 10.3.5. Charles River Laboratories
    • 10.3.5.1. Company Overview
    • 10.3.5.2. Financial Performance
    • 10.3.5.3. Service Benchmarking
    • 10.3.5.4. Strategic Initiatives
  • 10.3.6. ICON Plc
    • 10.3.6.1. Company Overview
    • 10.3.6.2. Financial Performance
    • 10.3.6.3. Service Benchmarking
    • 10.3.6.4. Strategic Initiatives
  • 10.3.7. Wuxi AppTec Inc.
    • 10.3.7.1. Company Overview
    • 10.3.7.2. Financial Performance
    • 10.3.7.3. Service Benchmarking
    • 10.3.7.4. Strategic Initiatives
  • 10.3.8. Medpace
    • 10.3.8.1. Company Overview
    • 10.3.8.2. Financial Performance
    • 10.3.8.3. Service Benchmarking
    • 10.3.8.4. Strategic Initiatives
  • 10.3.9. Syneos Health
    • 10.3.9.1. Company Overview
    • 10.3.9.2. Financial Performance
    • 10.3.9.3. Service Benchmarking
    • 10.3.9.4. Strategic Initiatives
  • 10.3.10. AstraZeneca
    • 10.3.10.1. Company Overview
    • 10.3.10.2. Financial Performance
    • 10.3.10.3. Service Benchmarking
    • 10.3.10.4. Strategic Initiatives
  • 10.3.11. Merck & Co.
    • 10.3.11.1. Company Overview
    • 10.3.11.2. Financial Performance
    • 10.3.11.3. Service Benchmarking
    • 10.3.11.4. Strategic Initiatives
  • 10.3.12. Eli Lilly and Company
    • 10.3.12.1. Company Overview
    • 10.3.12.2. Financial Performance
    • 10.3.12.3. Service Benchmarking
    • 10.3.12.4. Strategic Initiatives
  • 10.3.13. Novo Nordisk A/S
    • 10.3.13.1. Company Overview
    • 10.3.13.2. Financial Performance
    • 10.3.13.3. Service Benchmarking
    • 10.3.13.4. Strategic Initiatives
  • 10.3.14. Pfizer
    • 10.3.14.1. Company Overview
    • 10.3.14.2. Financial Performance
    • 10.3.14.3. Service Benchmarking
    • 10.3.14.4. Strategic Initiatives
  • 10.3.15. Caidya
    • 10.3.15.1. Company Overview
    • 10.3.15.2. Financial Performance
    • 10.3.15.3. Service Benchmarking
    • 10.3.15.4. Strategic Initiatives

관련자료